Wall Street brokerages expect Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) to report ($1.29) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Praxis Precision Medicines’ earnings. The lowest EPS estimate is ($1.41) and the highest is ($1.18). Praxis Precision Medicines reported earnings of ($0.71) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 81.7%. The firm is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Praxis Precision Medicines will report full year earnings of ($5.25) per share for the current year, with EPS estimates ranging from ($6.07) to ($4.75). For the next year, analysts anticipate that the firm will report earnings of ($5.29) per share, with EPS estimates ranging from ($6.31) to ($4.56). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Praxis Precision Medicines.
Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) last posted its earnings results on Monday, February 28th. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.22).
Hedge funds have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd bought a new stake in Praxis Precision Medicines during the fourth quarter valued at $31,000. Royal Bank of Canada grew its position in shares of Praxis Precision Medicines by 93.6% during the second quarter. Royal Bank of Canada now owns 1,673 shares of the company’s stock worth $31,000 after acquiring an additional 809 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth about $56,000. Ensign Peak Advisors Inc bought a new position in shares of Praxis Precision Medicines during the fourth quarter worth about $86,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of Praxis Precision Medicines by 29.5% during the fourth quarter. Cubist Systematic Strategies LLC now owns 9,599 shares of the company’s stock worth $189,000 after acquiring an additional 2,189 shares during the last quarter. Hedge funds and other institutional investors own 96.52% of the company’s stock.
Praxis Precision Medicines Company Profile (Get Rating)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.
- Get a free copy of the StockNews.com research report on Praxis Precision Medicines (PRAX)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.